Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Hologic, Inc. to funds managed by Blackstone and TPG for Hologic shareholders [1] Transaction Details - Hologic shareholders are set to receive $76.00 per share in cash [1] - Additionally, shareholders will receive a non-tradable contingent value right to receive up to $3.00 per share, payable in two installments of up to $1.50 each [1]

Core Viewpoint - Hologic has reached a final acquisition agreement with Blackstone and TPG, valuing the company at up to $79 per share and an enterprise value of up to $18.3 billion [1] Group 1: Acquisition Details - Blackstone and TPG will acquire all outstanding shares of Hologic at $76 per share in cash [1] - An additional non-tradable contingent value right allows shareholders to receive up to $3 per share in two installments, contingent on meeting specific revenue targets in Hologic's breast health business for fiscal years 2026 and 2027 [1]

Core Viewpoint - Blackstone and TPG have agreed to acquire all outstanding shares of a women's health company for $76 per share in cash [1] Company Summary - The acquisition involves a cash payment of $76 for each share of the women's health company [1]

Core Viewpoint - Blackstone and TPG are set to acquire Hologic for up to $18.3 billion, marking a significant healthcare take-private transaction in 2023 [1] Group 1: Acquisition Details - The acquisition price is $76 per share in cash, representing a nearly 6% premium over Hologic's last closing price [1] - Shareholders may receive a non-tradable right to an additional $3 per share, contingent on achieving specific global revenue targets for the breast health business in fiscal years 2026 and 2027, potentially raising the total payout to $79 per share [2] Group 2: Company Performance - Hologic specializes in women's health diagnostics, including breast and cervical cancer screening and infectious disease testing [2] - The company has experienced steady growth in its molecular diagnostics business but has indicated ongoing weakness in the breast health segment [3] Group 3: Transaction Timeline - The deal is anticipated to close in the first half of 2026 [3]

Core Viewpoint - Blackstone and TPG have reached an agreement to acquire Hologic, a medical diagnostics firm, in a deal valued at up to $18.3 billion [1] Company Summary - The acquisition involves two major investment firms, Blackstone and TPG, indicating strong interest in the medical diagnostics sector [1] - Hologic is positioned within the healthcare industry, specifically focusing on medical diagnostics, which is a critical area for investment given the ongoing demand for healthcare solutions [1] Financial Summary - The total deal value for the acquisition of Hologic is up to $18.3 billion, highlighting the significant financial commitment from Blackstone and TPG [1]

Core Viewpoint - Hologic is set to be acquired by Blackstone and TPG for up to $79 per share, indicating a significant valuation for the company [1] Group 1 - The acquisition price of up to $79 per share reflects a premium over Hologic's current market valuation [1] - Blackstone and TPG are prominent private equity firms, suggesting a strategic investment in the healthcare sector [1] - This acquisition could lead to potential growth opportunities for Hologic under the management of experienced private equity investors [1]

Group 1 - The proposal involves Blackstone and TPG acquiring Hologic in a take-private deal valued at up to $18.3 billion [8] - Hologic's stockholders would receive $76 per share, with an additional potential $3 per share based on revenue goals for the breast health business in fiscal years 2026 and 2027, representing a 46% premium to the stock's closing price on May 23 [4][8] - The deal includes debt financing commitments from major banks and equity commitments from Blackstone and TPG, along with minority investments from the Abu Dhabi Investment Authority and GIC [5] Group 2 - Hologic's board has unanimously approved the acquisition, which is expected to close in the first half of 2026, pending shareholder and regulatory approval [8] - Analysts suggest that the offered price is fair and that other bidders are unlikely due to Hologic's slower revenue growth and potential antitrust issues in the U.S. mammography market [6]

Core Viewpoint - TPG Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have a strong correlation with near-term stock price movements [4][6]. - TPG Inc. is expected to earn $2.46 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 21.5% over the past three months [8]. Institutional Investor Influence - Institutional investors play a significant role in stock price movements by adjusting their valuations based on earnings estimates, leading to buying or selling actions that affect stock prices [4]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - TPG Inc.'s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Hologic (NASDAQ:HOLX) rose 2% in premarket trading after a report about financing for a potential takeover by Blackstone (BX) and TPG Inc. (TPG). Direct lenders are preparing a $9 billion debt financing package as they attempt to compete with banks to ...

LONDON--(BUSINESS WIRE)--Tide, the UK's leading business management platform, today announced a strategic investment from TPG, a leading global alternative asset management firm. The investment raises Tide's valuation to $1.5 billion and marks a significant milestone in the Company's growth journey. The funding will accelerate Tide's international expansion, support rapid product development and advance its investment into agentic AI. The primary and secondary investment, which totals over $120. ...